First participants dosed in Phase 2/3 Study of Moderna’s COVID-19 vaccine candidate in adolescents

The randomised controlled Phase 2/3 study will evaluate the safety and immunogenicity of the mRNA-1273 vaccine, in two doses given 28 days apart, in healthy adolescents aged 12-18 years.

Source:

Biospace Inc.